SUPERCUT! Turns out everything @BarackObama said to sell ObamaCare was one big fat lie after another

Not recalling Obama saying after ObamaCare passes we'll need annual premium subsidies so Americans don't go bankrupt

$IOVA WAIT FOR $2.51 BREAK!!

$2.50 - check!

Hopefully Katie doesn’t pour hot mashed potatoes on me for correcting her but… restrictions for private jets are already in place!

Held two more property tax round tables in western Iowa, visiting with community leaders and business owners in Corning and Council Bluffs. Grateful for everyone’s insights and ideas for delivering lower property taxes in the next legislative session.

Today we reported third quarter and year to date 2025 financial results, business achievements and pipeline milestones. We hosted an audio webcast at 8:30 am ET today, listen to our audio webcast here: ir.iovance.com/events/event-…

In the wake of the hubbub on novel promising gene therapy approval for Huntington’s disease, this video on the Sarepta debacle is a must watch. She knew. Yesterday Sarepta finally reported on their confirmatory trials : Negative.

And here you have it, folks: Democrat Party elites view Mamdani as much bigger than New York City. Mamdani-ism is a national project. Buckle up!!!

If you boil it down to simple facts, the Democrats have shut down the government to protest Republicans allowing Obamacare to operate as intended by Democrats who wrote it, passed it and implemented it without any Republican votes.

His son is a gay man. He is depressed when he begins his transition and remains depressed after transitioning. He enters a relationship with a bisexual man who later himself transitions. Along the way, his son marries a woman who dates others men. His son is 26 years old at the start of this, living in Berlin and working as a designer and DJ. This is where transgenderism belongs -- in the urban art and fashion demimonde, one of many other by now rote, hackneyed subcultural lifestyle eccentricities that are no longer new and no longer interesting but which continue as modes of self-expression for bored, disaffected children of elites in ostensible revolt against a society that does nothing but indulge and praise and coddle their ostensible revolt. Where it does not belong: in your child's kindergarten classroom, in your daughter's middle school changing room, dunking a volleyball on your daughter's head, embedded in constitutional law.

Why Biotechs got hammered today… even $iova #iova with very appealing data!

🧵"Karine Jean-Pierre can't stop making history. Earlier this year, the former White House press secretary became the highest-ranking openly queer, French-born black woman with a hyphenated surname to publicly renounce the Democratic Party for being mean to Joe Biden."

$IOVA NSCLC Reaction These results are solid. What I like the most here is the 2 complete responses. I look forward to them publishing graphs showing individual response rates. When this is part of a drug combo, the results should get even better. So, this is a solid foundation to build upon. The financials will probably be bad on Nov 6. If so, it will be a buying opportunity for those who understand that these results are more important to the long-term future of this company. Key Results: The objective response rate (ORR) was 25.6% by RECIST v1.1 following one-time treatment with lifileucel monotherapy in patients with advanced nonsquamous NSCLC. An objective response was observed in 10 out of 39 patients, including 2 complete responses, 7 partial responses (PRs), and 1 unconfirmed PR (pending confirmatory assessment), with a disease control rate of 71.8%.1 The median duration of response (mDOR) was not reached after a median follow up of 25.4 months.

$iova #iova what Mizuho says about the fresh data and TP $10…. Is there a manipulation? Absolutely! Biotech sector yes under pressure, but given strong data, the price action is very odd….

We announced positive interim data for our one-time cell therapy in advanced NSCLC: ir.iovance.com/news-releases…

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) $IOVA tinyurl.com/2cyjryn4

$IOVA +11% after Phase 2 registrational data showed ORR 25.6% (10/39) with 2 CRs and FDA positive feedback, expects sBLA 2026 and launch H2 2027 stocktitan.net/news/IOVA/iov…

$IOVA -- Strong Resurgence in Cell Therapy Q2 Revenue Exceeds $60 Million, Up 93% Year-over-Year Iovance Biotherapeutics' performance has surged as TIL therapy gains momentum. Significant progress has been made in melanoma treatment, with expansion into new cancer indications

$IOVA - lifileucel showed a 25.6% response rate in advanced nonsquamous NSCLC, including 2 complete responses - 71.8%; median duration of response not yet reached after 25.4 months - FDA gave positive feedback on the trial design, supporting potential accelerated approval - sBLA filing expected in 2026, with a possible launch in late 2027 - Updated regimen improved safety and reduced hospital time without lowering efficacy